Novartis and Pear Therapeutics to Develop Digital Therapeutics for Patients with Schizophrenia and Multiple Sclerosis
Novartis has entered into a collaboration with Pear Therapeutics to develop novel prescription digital therapeutics, software applications designed to effectively treat disease and improve clinical outcomes for patients. The collaboration brings together Novartis expertise in biomedical research and clinical development with Pear's leading experience in digital therapeutics design and implementation. 
Ahead of the 2018 Annual Healthcare Information and Management Systems Society (HIMSS) Conference, Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, announced the Philips eICU program has helped Avera Health, a South Dakota-based integrated health system, enhance care quality and efficiency by partnering to deliver significant clinical and financial outcomes through the ICU division of their telemedicine program, Avera eCARE®. 
Allscripts (NASDAQ:MDRX) has signed a definitive agreement to sell its OneContent business to Hyland Software, Inc., a leading provider of content services solutions to the healthcare industry and beyond. The deal is expected to close in the second quarter once customary closing conditions are satisfied. 
Today, the U.S. Food and Drug Administration permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients. 
Abbott (NYSE: ABT) announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones(2) (both iPhone and Android). People with diabetes living in Europe and using the FreeStyle® Libre system(3) are now able to access glucose data directly from their smartphones, eliminating the need to carry the separate FreeStyle Libre reader(4) (a handheld device used to scan the FreeStyle Libre sensor to get a glucose result).